v3.26.3
STOCKHOLDERS EQUITY
9 Months Ended
Sep. 30, 2026
STOCKHOLDERS EQUITY  
STOCKHOLDERS' EQUITY

NOTE 15 – STOCKHOLDERS’ EQUITY

 

As at September 30, 2026 and December 31, 2025, the Company’s issued and outstanding common stock was 2,933,442 and 2,417,314 shares, respectively.

 

Reverse Stock Split

 

On March 19, 2025, the Company held a Special Meeting of Shareholders which, among other items, approved of an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding shares of common stock, with a ratio ranging from one-for-five (1:5) to one-for-ten (1:10), with the exact ratio to be set at the discretion of the Board of Directors. Thereafter, on that same date, the Board of Directors set the reverse stock split ratio at 1 for 10.

 

On April 1, 2025, the Company filed its Articles of Amendment with the Wyoming Secretary of State to effect a one for ten (1 for 10) reverse stock split of its issued and outstanding common stock, which became market effective on April 7, 2025. Immediately prior to the reverse stock split, the Company had 17,967,663 shares of common stock issued and outstanding and immediately after the reverse stock split, the Company had 1,796,597 shares of common stock issued and outstanding. No fractional shares were issued in connection with the reverse stock split. Instead, shareholders who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof based on the daily Volume Weighted Average Price (VWAP) of our common stock, calculated for ten (10) trading days immediately preceding the effective date of the Reverse Stock Split, multiplied by the fractional share.

 

Shelf Filing

 

On November 7, 2025, the Company filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) to register up to $100 million of securities that may be offered from time to time. The Company concurrently entered into an Equity Distribution Agreement (the “Agreement”) with Maxim Group LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, shares of its common stock, no par value (the “Common Stock”), having an aggregate offering price of up to $20,000,000 through the Agent, acting as the Company’s exclusive sales agent (the “ATM Program”).

 

Sales, if any, will be made in transactions deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, which may be made directly on The Nasdaq Capital Market or otherwise at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices, as permitted by the Agreement. The Company is not obligated to sell any shares under the ATM Program, and the Agent is not required to purchase any shares. The Form S-3 became effective on November 27, 2025. As of the date of this report, the Company had sold 53,478 shares under the ATM Program for proceeds of $267,311, all of which were sold in 2025.

 

Additional Share Issuances

 

In November 2025, the Company issued 175,000 shares of common stock to ARC Group International Ltd. (“ARC”) as consideration for ARC’s commitment under the purchase agreement to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share, over a 36-month period. As of the date of this report, ARC has not purchased any shares under the purchase agreement.

 

In November 2025, the Company issued 392,329 shares of common stock to Fidelion Diagnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This issuance was a result of the Share Subscription and Shareholders’ Agreement with Fidelion and Tongshu Biotechnology (Hong Kong) Co., Limited, among others, which closed on November 28, 2025.

 

On August 13, 2026, the Company issued an aggregate of 516,128 shares of its common stock, no par value per share, under the Company’s shareholder-approved 2025 Equity Incentive Plan. Each award was a fully vested Other Stock-Based Award under Section 5 of the plan, issued on a bonus basis as compensation for completed services and for no cash consideration. The awards were measured at a grant-date fair value of $1.55 per share, based on the Nasdaq closing price on August 12, 2026, the last closing price before the awards were granted, for an aggregate of $799,998, which was recognized as share-based compensation expense in the three-month period ended September 30, 2026.